http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20150043032-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S424-801 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4707 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate | 2013-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20150043032-A |
| titleOfInvention | Pharmaceutical use of STIM1 |
| abstract | The present invention relates to the pharmaceutical use of STIM1, wherein the C-terminus of STIM1, that is, the SERCA1a-binding region (STIM1-SBR: amino acid sequence region of STIM1-SBR: 449-671) inhibits the activity of the lysozyme receptor calcium channel, STIM1-SBR inhibitor can be used to control the total amount of STIM1 protein to inhibit the activity of the calcium channel of the ryanodine receptor and to promote skeletal muscle contraction, thereby preventing or treating muscle tension-lowering diseases with skeletal muscle contraction disorder. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190114205-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210115100-A |
| priorityDate | 2013-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 264.